Aticaprant
Small moleculeexperimental
Clinical trial activity
10 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
6
Phase 3
5
Phase 4
0
Earliest trial started Jul 16, 2018 (NCT03559192)
Timeline
Indications
Mechanism of action
- Kappa opioid receptorANTAGONIST
Kappa opioid receptor antagonist
Chemistry & pharmacology
Loading structure…
SMILES
Cc1cc(C)cc([C@@H]2CCCN2Cc2ccc(Oc3ccc(C(N)=O)cc3F)cc2)c1- Mol. weight
- 418.51 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL1921847 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06635135 | Phase 3 | Sep 19, 2024 | — |
| NCT06514742 | Phase 3 | Jun 26, 2024 | — |
| NCT05550532 | Phase 3 | Oct 28, 2022 | — |
| NCT05518149 | Phase 3 | Sep 22, 2022 | — |
| NCT05455684 | Phase 3 | Jun 22, 2022 | — |
| NCT05387759 | Phase 1 | May 30, 2022 | — |
| NCT05197062 | Phase 1 | Jan 14, 2022 | — |
| NCT04791332 | Phase 1 | Apr 30, 2021 | Janssen Pharmaceutica NV |
| NCT04185051 | Phase 1 | Feb 16, 2020 | Janssen Pharmaceutica NV |
| NCT03559192 | Phase 2 | Jul 16, 2018 | Johnson and Johnson |
Showing 10 of 10 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Janssen Pharmaceutica NV | For profit | 2 | 2 | 1 | 2020 |
| Johnson and Johnson | For profit | 1 | 1 | 1 | 2018 |
2 organizations
Page 1 / 1